Patent intelligence · US
US 11691011
Pain-relieving apparatus
Pain-relieving apparatus
Patent details — US 11691011
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 4, 2023
- Expiration
- Jun 29, 2043
- Applicant
- Black Diamond Creations, LLC
- Claims
- 4
- CPC classes
- A61K, A61K31/167, A61K9/7007
Quick answer
US 11691011 (Pain-relieving apparatus) is held by Black Diamond Creations, LLC. Status: granted. Granted Jul 4, 2023. Expires Jun 29, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Black Diamond Creations, LLC
- Grant date
- Expiration
- Claims
- 4
- CPC classes
- A61K, A61K31/167, A61K9/7007
More from Black Diamond Creations, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12343394
CD38 modulating antibody agents
granted -
US 12325699
Antibacterial compounds
granted -
US 12304964
CD38 modulating antibody
granted -
US 12187754
LpxC inhibitors and uses thereof
granted -
US 12161717
CD38 modulating antibody agents
granted -
US 12162949
CD38 antibody
granted -
US 11897873
Kappa opioid receptor antagonists and products and methods related thereto
granted -
US 11780930
CD38 modulating antibody
granted
Frequently asked questions
What is US patent 11691011?
US 11691011 (Pain-relieving apparatus) is held by Black Diamond Creations, LLC. Status: granted. Granted Jul 4, 2023. Expires Jun 29, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11691011?
Black Diamond Creations, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 11691011 expire?
Our index shows an expiration date of Jun 29, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.